NCT00569751已完成4 期
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 5,016
- 试验地点
- 105
- 主要终点
- Rate of TAXUS stent related cardiac events as classified by the Clinical Events Committee (CEC).
研究概览
简要总结
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Rate of TAXUS stent related cardiac events as classified by the Clinical Events Committee (CEC).
时间窗: 1-year post-implant procedure
次要结局
- Rate of TAXUS stent related cardiac events as classified by the CEC.(within 30 days, 6 months and 2 years)
- Rate of target vessel related cardiac events as classified by the CEC.(30 days, at 6 months, at 1 and 2 years post-implant procedure)
- Rate of other TAXUS related events(30 days, 6 months, 1 and 2 years post-implant procedure)
研究者
研究点 (105)
Loading locations...
相似试验
已完成
4 期
TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance ProgramCoronary Artery DiseaseNCT00569491Boston Scientific Corporation2,585
已完成
2 期
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary LesionsCoronary StenosisNCT00301522Boston Scientific Corporation1,108
已完成
不适用
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)Congenital Factor VIII (FVIII) DeficiencyHemophilia ANCT02093741Baxalta now part of Shire65
已完成
不适用
A prospective, non-randomized, multi-center, open-label clinical investigation to assess the safety and technical performance of the Emboliner embolic protection catheter.ACTRN12619000179134Emboline, Inc.31
Unknown
2 期
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver FunctionHepatocellular CarcinomaNCT04454762Johannes Gutenberg University Mainz20